November 2025 International Monthly Webinar
Date: Thursday, November 20
Time: 2 p.m. EST
Each month, we bring together voices from across the oncology care spectrum to share what’s new, what’s working, and what’s next. This month, we’re diving into upcoming legislative changes, optimized access pathways, evolving pricing models, and new clinical insights for ibrutinib and Vyloy®.
This Month’s Lineup:
Opening remarks from Heather Maynard, CPhT, COPhT (UW Health)
Oncology Legislative Update 2026: Preparing for What’s Ahead – Jonas Congelli, RPh & Douglas Braun, CSP, PharmD, CSP (NCODA), will walk through the major policy and legislative changes coming in 2026—and what oncology practices should be preparing for now. They’ll highlight what’s expected to shift, what it may mean for care teams, and how to stay ahead of evolving requirements.
Transforming Access in Oncology: NCODA’s Oncology Optimized Limited Distribution Model – Jonas Congelli, RPh & Douglas Braun, CSP, PharmD, CSP (NCODA), will break down NCODA’s Oncology Optimized Limited Distribution (OOLD) model—how it works, why it matters, and how it supports coordinated, patient-centered oncology care. Jonas and Doug will discuss how OOLD helps minimize PBM-driven mail-order disruptions and strengthens in-practice access for patients.
Imbruvica® MFP Pricing: What Practices Need to Know – Douglas Braun, CSP, PharmD, CSP (NCODA) will explain the upcoming Maximum Fair Price (MFP) changes for ibrutinib (Imbruvica®)—including timelines, reimbursement expectations, and what won’t change (like NDCs). He’ll also cover practical steps for navigating the chargeback window (Dec 15–22) and managing inventory through the shift from legacy WAC to new WAC/MFP reimbursement.
Positive Quality Intervention (PQI): Optimizing Ibrutinib Dosing – Nicole Bentivegna, PharmD, BCOP (Florida Cancer Specialists & Research Institute), will take a practical look at optimizing ibrutinib (Imbruvica®) therapy—when to adjust dosing, what to monitor, and how to manage common toxicities. She’ll discuss cardiac and non-cardiac considerations, supportive care strategies, and how patient-specific factors (like comorbidities, labs, and drug interactions) can guide clinical decisions.
Vyloy® (zolbetuximab-clzb): Safe and Effective Use in Gastroesophageal Cancers – Andrew Ruplin, PharmD (UW Medicine), will review how to identify appropriate candidates for zolbetuximab-clzb, including HER2 and CLDN18.2 requirements. He’ll also cover strategies to prevent and manage nausea and vomiting, plus practical guidance for administering Vyloy safely—particularly around hypersensitivity risk.
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.
Login to Watch this Webinar
To watch the live webinar, login to your account or register to gain access to our exclusive content.
Additional Upcoming Webinars
November 18, 2025 | 2:00 PM
Upcoming Webinar
Pharmacy Perspectives: Emotional Support, Efficiency, and Feedback in Pharmacy Practice
November 18, 2025 | 5:00 PM
Upcoming Webinar
Mesothelioma in Focus: From Diagnosis to Coordinated Care
November 19, 2025 | 2:00 PM